JP6779232B2 - ウイルス感染の治療又は予防のための新規オキサチオランカルボン酸と誘導体 - Google Patents

ウイルス感染の治療又は予防のための新規オキサチオランカルボン酸と誘導体 Download PDF

Info

Publication number
JP6779232B2
JP6779232B2 JP2017558025A JP2017558025A JP6779232B2 JP 6779232 B2 JP6779232 B2 JP 6779232B2 JP 2017558025 A JP2017558025 A JP 2017558025A JP 2017558025 A JP2017558025 A JP 2017558025A JP 6779232 B2 JP6779232 B2 JP 6779232B2
Authority
JP
Japan
Prior art keywords
thiazolo
amino
pyrimidin
compound
dioxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017558025A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018515503A (ja
JP2018515503A5 (enExample
Inventor
リウ，ハイシア
ウー，グオローン
ユイン，ホーンイーン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2018515503A publication Critical patent/JP2018515503A/ja
Publication of JP2018515503A5 publication Critical patent/JP2018515503A5/ja
Application granted granted Critical
Publication of JP6779232B2 publication Critical patent/JP6779232B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2017558025A 2015-05-08 2016-05-04 ウイルス感染の治療又は予防のための新規オキサチオランカルボン酸と誘導体 Expired - Fee Related JP6779232B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2015078578 2015-05-08
CNPCT/CN2015/078578 2015-05-08
PCT/EP2016/059949 WO2016180691A1 (en) 2015-05-08 2016-05-04 Novel oxathiolane carboxylic acids and derivatives for the treatment and prophylaxis of virus infection

Publications (3)

Publication Number Publication Date
JP2018515503A JP2018515503A (ja) 2018-06-14
JP2018515503A5 JP2018515503A5 (enExample) 2019-06-06
JP6779232B2 true JP6779232B2 (ja) 2020-11-04

Family

ID=55910268

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017558025A Expired - Fee Related JP6779232B2 (ja) 2015-05-08 2016-05-04 ウイルス感染の治療又は予防のための新規オキサチオランカルボン酸と誘導体

Country Status (5)

Country Link
US (1) US10183954B2 (enExample)
EP (1) EP3294745B1 (enExample)
JP (1) JP6779232B2 (enExample)
CN (1) CN107743491B (enExample)
WO (1) WO2016180691A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021009496A (es) 2019-02-08 2021-09-08 Progeneer Inc Complejo de colesterol-agonista del receptor 7 u 8 tipo larga distancia, y uso del mismo.
JP2023516372A (ja) 2020-03-02 2023-04-19 プロジェニア インコーポレイテッド 病原菌外壁成分基盤の生病原体模倣ナノ粒子及びその製造方法
JP2023536954A (ja) 2020-08-04 2023-08-30 プロジェニア インコーポレイテッド 活性化部位が一時的に不活性化したトール様受容体７または８作用薬と機能性薬物の結合体およびその用途
JP7690222B2 (ja) 2020-08-04 2025-06-10 プロジェニア インコーポレイテッド 動力学的制御が可能なアジュバントを含むｍＲＮＡワクチン
EP4194008A4 (en) 2020-08-04 2025-01-08 Progeneer Inc. Kinetically acting adjuvant ensemble

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476659A (en) 1982-11-09 1995-12-19 The Scripps Research Institute Cancerous B cell treatment using substituted nucleoside derivatives
US5166141A (en) 1983-11-01 1992-11-24 Scripps Clinic And Research Foundation Immunostimulating 7-deaza-7-oxa- and 7-deaza-7-oxo-analogs of 8-substituted-guanine-9-(1'-beta-D-aldoglycosidyl) derivatives and methods of treating test animals
US5041426A (en) 1987-12-21 1991-08-20 Brigham Young University Immune system enhancing 3-β-d-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and nucleotides
US5248776A (en) * 1990-12-05 1993-09-28 University Of Georgia Research Foundation, Inc. Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides
EP1072607A3 (en) 1996-10-16 2001-09-12 ICN Pharmaceuticals, Inc. Purine L-nucleosides, analogs and uses therof
CA2266889A1 (en) 1996-10-16 1998-04-23 Guangyi Wang Purine l-nucleosides, analogs and uses thereof
EP1382343B1 (en) * 1998-11-02 2010-02-17 Gilead Sciences, Inc. Combination therapy to treat hepatitis B virus
EP1411954B1 (en) * 2000-10-18 2010-12-15 Pharmasset, Inc. Modified nucleosides for treatment of viral infections and abnormal cellular proliferation
AU2002329970A1 (en) * 2001-09-04 2003-03-18 Isis Pharmaceuticals, Inc. Pyrrolo(2,3-d)pyrimidines for inhibiting rna-dependent rna viral polymerase
US20050004144A1 (en) 2003-04-14 2005-01-06 Regents Of The University Of California Combined use of IMPDH inhibitors with toll-like receptor agonists
WO2005025583A2 (en) 2003-09-05 2005-03-24 Anadys Pharmaceuticals, Inc. Tlr7 ligands for the treatment of hepatitis c
CN101212968B (zh) * 2004-12-17 2011-11-16 安那迪斯药品股份有限公司 3,5-二取代的和3,5,7-三取代的-3H-噁唑并以及3H-噻唑并[4,5-d]嘧啶-2-酮化合物及其前药
KR101320008B1 (ko) 2004-12-17 2013-10-18 애나디스 파마슈티칼스, 인코포레이티드 ３，５-이치환 및 ３，５，７-삼치환된-３Ｈ-옥사졸로 및３Ｈ-티아졸로 〔４，５-ｄ〕피리미딘-2-온 화합물 및 이의전구약물
AR053347A1 (es) * 2005-04-06 2007-05-02 Astrazeneca Ab Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos
CL2007001427A1 (es) 2006-05-22 2008-05-16 Novartis Ag Sal de maleato de 5-amino-3-(2',3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d]pirimidin-2-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una infeccion po
KR101461604B1 (ko) 2006-06-22 2014-11-18 애나디스 파마슈티칼스, 인코포레이티드 5-아미노-3-(3''-데옥시-β-Ｄ-리보퓨라노실)-티아졸로［4,5-ｄ］파이리미딘-2,7-다이온의 프로드럭
EP2040712B1 (en) 2006-07-18 2011-03-02 Anadys Pharmaceuticals, Inc. Carbonate and carbamate prodrugs of thiazolo [4,5-d] pyrimidines
BRPI0717741A2 (pt) 2006-10-17 2014-04-08 Anadys Pharmaceuticals Inc Compostos e respectivos método de preparação, método de redução de composto de sulfonil substituído, composição farmacêutica método de tratamento ou prevenção de doença
WO2009026292A1 (en) 2007-08-20 2009-02-26 Anadys Pharmaceuticals, Inc. Dosing methods for treating disease
UA111640C2 (uk) * 2011-11-08 2016-05-25 Ф. Хоффманн-Ля Рош Аг ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2
CN104230952B (zh) * 2014-08-16 2017-02-01 沈阳药科大学 含有嘧啶骨架的化合物及其制备方法和用途
CN107001386A (zh) * 2014-10-11 2017-08-01 豪夫迈·罗氏有限公司 用于治疗感染性疾病的化合物

Also Published As

Publication number Publication date
US20180065991A1 (en) 2018-03-08
EP3294745A1 (en) 2018-03-21
US10183954B2 (en) 2019-01-22
JP2018515503A (ja) 2018-06-14
CN107743491A (zh) 2018-02-27
WO2016180691A1 (en) 2016-11-17
EP3294745B1 (en) 2020-01-01
HK1250709A1 (zh) 2019-01-11
CN107743491B (zh) 2020-08-21

Similar Documents

Publication Publication Date Title
JP6806709B2 (ja) ウイルス感染症の治療と予防のための新規置換アミノチアゾロピリミジンジオン
US10975098B2 (en) Substituted aminothiazolopyrimidinediones for the treatment of virus infection
JP6568106B2 (ja) Ｂ型肝炎ウイルス感染症の治療及び予防のための新規ジヒドロキノリジノン類
JP6553825B2 (ja) 抗がん剤として有用な置換カルボヌクレオシド誘導体
JP6817217B2 (ja) ウイルス感染症の治療および予防のための３−置換された５−アミノ−６Ｈ−チアゾロ［４，５−ｄ］ピリミジン−２，７−ジオン化合物
TWI840646B (zh) 作為jak抑制劑之聯吡唑衍生物
EP2855476B1 (en) Tetrahydropyrazolopyrimidine compounds
JP2021191764A (ja) ジアゼピノン誘導体及びｂ型肝炎感染症の治療におけるその使用
JP6779232B2 (ja) ウイルス感染の治療又は予防のための新規オキサチオランカルボン酸と誘導体
JP2019516714A (ja) 感染症の治療のための酸素、硫黄および窒素リンカーを有する新規ピラジン化合物
JP2020528062A (ja) ピペラジンヘテロアリール誘導体、その製造方法、およびその医薬での使用
JP2018514575A (ja) Ｂ型肝炎ウイルス感染症の治療用のＨＢｓＡｇ（ＨＢＶ表面抗原）及びＨＢＶ ＤＮＡ産生の阻害剤としてのテトラヒドロピリドピリミジン類及びテトラヒドロピリドピリジン類
KR20170113658A (ko) Tlr7 작용제 및 hbv 캡시드 조립 억제제를 사용하는 병용 치료
JP2017531655A (ja) 感染性疾患の処置に使用するための化合物
TW202321246A (zh) Prmt5抑制劑
JP2023536891A (ja) 重症肺炎を治療するためのｊａｋ阻害剤化合物
KR20100136469A (ko) 피롤로피리미딘카르복시아미드
CN102574861A (zh) 甲基吡咯并嘧啶甲酰胺
HK1250709B (zh) 用於治疗和预防病毒感染的新的氧硫杂环戊烷甲酸及其衍生物
JP7328977B2 (ja) ウイルス感染の処置および予防のための新規のスルホン化合物および誘導体
HK1248711B (zh) 用於治疗和预防病毒感染的新的取代的氨基噻唑并嘧啶二酮
HK1251554B (zh) 用於治疗和预防病毒感染的取代的氨基噻唑并嘧啶二酮

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190426

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190426

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200213

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200213

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200804

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200916

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201013

R150 Certificate of patent or registration of utility model

Ref document number: 6779232

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees